Building what comes next in obesity care.
Modern weight-loss medicines are transforming obesity care, delivering powerful results while creating new challenges. As people eat less, their nutritional needs, digestion and physical wellbeing may change. Achieving better weight loss means looking beyond the kilograms lost — supporting health, wellbeing and quality of life throughout the weight-loss journey.
Azento Health develops science-led companion products for this new treatment environment.
SCIENCE
Built on evidence. Not borrowed claims.
We combine obesity science, microbiome research, patient insight and product-specific evidence to build solutions around the real needs emerging in modern weight management.
SUPPORT
Designed around the journey.
The needs of someone starting treatment are different from those of someone actively losing weight, maintaining progress or transitioning after treatment. Our products and pipeline are built around those changing needs.
HEALTH & HAPPINESS
Success is more than kilograms lost.
Weight matters. So do health, function, confidence and how people experience the journey. That is what Better Weight Loss means to us.
Swiss Research — Manufactured in Europe. Built for modern weight management.
A new obesity economy is forming around increasingly powerful medicines.
Modern obesity medicines have already created one of healthcare’s fastest-moving categories.
$66B
global obesity-medicine sales in 2025 (approximately).[1]
$105–200B
market range forecast by IQVIA from 2027 onward.[1]
193+
anti-obesity assets in development as of October 2025, estimated by IQVIA.[2]
GLP-1s are not only creating a drug market. They are creating a new weight-loss ecosystem.
16–39%
reduction in total energy intake across GLP-1 studies
Powerful weight loss creates new support needs. Less appetite. More nutritional pressure.
Across GLP-1-based studies, total energy intake reductions of approximately 16–39% have been reported.[3,4] That therapeutic effect is powerful, but it also means protein, fibre, fluids, micronutrients and overall dietary quality increasingly have to fit into less food.
INSIGHTA smaller appetite does not create a smaller need for health.
93%
satisfied with the effect on body weight
62%
report reduced energy for daily activities
Efficacy and experience should coexist.
In a 2026 UK survey of 544 current or former GLP-1 users, 93% reported satisfaction with the medication’s effect on body weight, while 62% reported at least moderate reductions in energy affecting physical activity or everyday tasks.[8]
INSIGHTThe medicine can be working while the person still needs support.
77%
At least one side effect
60%
Two or more side effects
Side effects create different support needs.
In a BCG survey, 77% of GLP-1 users reported at least one side effect, while 60% experienced two or more.[6]
Digestive symptoms such as nausea, constipation, diarrhoea and vomiting are among the most common. Users also report fatigue, hair loss and concerns about muscle loss, highlighting the broad range of challenges that may accompany treatment.
INSIGHTDifferent people. Different side effects. Individual support needs.
64.8%
Discontinued within one year
36.3%
Restarted within a year of stopping
Weight-loss journeys are rarely linear.
In a US study of more than 125,000 GLP-1 users, 64.8% of those without type 2 diabetes discontinued treatment within one year. Among those who stopped, 36.3% restarted within the following year.
People start, stop and restart treatment for different reasons, including side effects, cost and changing weight-management needs. Each transition can bring new challenges and a need for continued support.
INSIGHTPeople start. People stop. People restart. Their needs continue to evolve.
Microbiome science built around modern weight loss.
The gastrointestinal tract sits at the intersection of food intake, digestion, nutrient exposure, microbial metabolism, immune signalling and metabolic health. Research into the relationship between GLP-1 therapies, weight loss and the gut microbiome is developing rapidly.
Azento Health created azh-biotics® as a microbiome science and development platform for this changing treatment environment.
The platform combines defined bacterial strains, evidence-informed formulation design, strain-level traceability and a growing programme of clinical, preclinical and real-world research.
THE WEIGHT-LOSS JOURNEY
One journey. Different needs. Stage-specific support.
Build a strong foundation.
As appetite and eating habits begin to change, gut health and good nutrition matter from day one. The focus is on supporting digestive wellbeing, vitamins, minerals, fibre intake, and hydration.
Our focus: Forte80®, DAILY, SYNBIOTIC and microbiome-based solutions.
Protect health while losing weight.
Successful weight loss is about more than kilograms lost. As food intake decreases, nutrition, hydration, muscle and bone health become increasingly important for overall wellbeing.
Our focus: Forte80®, DAILY, SYNBIOTIC, HYDRATE, MUSCLE & BONE and metabolic health concepts.
Make weight and health progress sustainable.
Long-term success depends on more than treatment alone. Healthy routines, balanced nutrition and physical wellbeing help people sustain progress and feel their best.
Our focus: DAILY, HYDRATE, STAY, MUSCLE, ENERGY, MAINTAIN and long-term maintenance solutions.
Support what comes next.
Reducing or stopping treatment can bring new challenges as appetite and weight dynamics change. Ongoing nutritional and lifestyle support can help people navigate the transition and manage the risk of weight regain.
Our focus: DAILY, STAY, MAINTAIN, nutrition, metabolic health and weight-maintenance solutions.